The Role of Matrix Metalloproteinase 2 and 9 Enzymes in Developing Chronic Thromboembolic Pulmonary Hypertension

NCT04773028 | Completed Results

• 1 other identifier: 2020-071
• Study Type: observational
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

Chronic thromboembolic pulmonary hypertension is an occlusive disease in pulmonary artery.Matrix metalloproteinase enzymes play a substantial role of extracellular matrix remodeling. The clot formed in chronic thromboembolic pulmonary hypertension does not melt and turns into a fibrous state, it occludes the pulmonary artery.In this study, investigators aimed to investigate the role of matrix metalloproteinase enzymes in pulmonary arterial wall remodeling in patients with chronic thromboembolic pulmonary hypertension

Conditions

Chronic Thromboembolic Pulmonary Hypertension

Outcome Measures

Primary Outcomes (1)

• Concentration of Matrix Metalloproteinase 2 and 9 Enzymes

  Measurement the concentration of matrix metalloproteinase 2 and 9 enzymes by elisa and western blot techniques.

  1 year

Study Arms (2)

PATİENT GROUP(GROUP 1)

This group is the group that underwent pulmonary thromboendarterectomy due to chronic thromboembolic pulmonary hypertension.Sample was taken from the material extracted from this group during operation.

Other: matrix metalloproteinase enzymes 2 and 9

CONTROL GROUP(GROUP 2)

This group is the group that underwent lobectomy or pneumonectomy for another reason that the pulmonary artery is not affected. Patients operated for a reason other than chronic thromboembolic pulmonary hypertension and samples were taken from the intact pulmonary artery of the removed lung.

Other: matrix metalloproteinase enzymes 2 and 9

Interventions

matrix metalloproteinase enzymes 2 and 9 OTHER

concentration of matrix metalloproteinase 2 and 9 enzymes

CONTROL GROUP(GROUP 2); PATİENT GROUP(GROUP 1)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Study population has chronic thromboembolic pulmonary hypertension and will be performed pulmonary thromboendarterectomy.

You may qualify if:

• Despite 3 months of anticoagulation therapy
• mean pulmonary arterial pressure \> 20 mmHg
• pulmonary vasculary resistance \> 3 wood
• pulmonary capillary wedge pressure \< 15 mmHg
• perfusion defect in ventilation perfusion scintigraphy
• pulmonary angiography or computed tomography angiography showing pulmonary artery occlusive lesions

You may not qualify if:

• Patients undergoing pulmonary thromboendarterectomy concomitant coronary bypass, carotid endarterectomy, aortic valve, ascending aorta, mitral valve, tricuspid valve, pulmonary valve surgery
• Patients who have undergone surgical or percutaneous procedures due to atherosclerotic disease

Sponsors & Collaborators

• AHMET ZENGIN: lead

Study Sites (1)

Kartal Kosuyolu High Speciality Training and Research Hospital

Istanbul, Eyalet/Yerleşke, 34800, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Samples was teken from pulmonary endarterectomy material during the operation. This material is removed routinly this surgical procedure. At this studt any extra surgical procedure did not performed to participans.

Results Point of Contact

• Title: Dr.Ahmet Zengin
• Organization: Kartal Kosuyolu Hihg Speciality Training and Research Hospital

dr.zenginahmet@gmail.com

+905365022173

Study Officials

• mehmet yanartas

  kartal kosuyolu hıgh specıalty training and research hospital

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: medical doctor

Study Record Dates

• First Submitted: February 19, 2021
• First Posted: February 26, 2021
• Study Start: July 1, 2020
• Primary Completion: May 4, 2021
• Study Completion: May 4, 2021
• Last Updated: August 10, 2021
• Results First Posted: August 10, 2021

Record last verified: 2021-08

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)